Related Experiment Video
Updated: Mar 21, 2026
Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
Published on: February 2, 2011
Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21
Srinivas S Somanchi1, Dean A Lee2
1Division of Pediatrics, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit # 853, Houston, TX, 77054, USA. sssomanchi@mdanderson.org.
Abstract:
Natural killer (NK) cells have gained significant attention for adoptive immunotherapy of cancer due to their well-documented antitumor function. In order to evaluate the therapeutic efficacy of NK cell adoptive immunotherapy in preclinical models with a potential for clinical translation, there is a need for a reliable platform for ex vivo expansion of NK cells. Numerous methods are reported in literature using cytokines and feeder cells to activate and expand human NK cells, and many of these methods are limited by low-fold expansion, cytokine dependency of expanded NK cells or expansion-related senescence. In this chapter, a robust NK cell expansion protocol is described using K562 cell line gene modified to express membrane bound IL21 (K562 mb.IL21). We had previously demonstrated that this platform enables the highest fold expansion of NK cells reported in the literature to date (>47,000-folds in 21 days), and produces highly activated and pure NK cells without signs of senescence, as determined by telomere shortening.
Insights
This study presents a novel method for expanding natural killer (NK) cells, crucial for cancer immunotherapy. The K562 mb.IL21 platform achieves unprecedented NK cell expansion without senescence, paving the way for clinical translation.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Natural killer (NK) cells are vital for adoptive cancer immunotherapy due to their antitumor properties.
- Effective NK cell adoptive immunotherapy requires reliable methods for ex vivo expansion.
- Existing expansion methods often suffer from low yields, cytokine dependence, or senescence.
Purpose of the Study:
- To describe a robust protocol for ex vivo expansion of human NK cells.
- To present a novel NK cell expansion platform using genetically modified K562 feeder cells.
- To address limitations of current NK cell expansion techniques for clinical translation.
Main Methods:
- Utilized a K562 cell line engineered to express membrane-bound interleukin-21 (K562 mb.IL21) as a feeder cell system.
- Developed a protocol for the ex vivo expansion of human NK cells using this feeder cell platform.
- Assessed NK cell expansion efficiency, purity, activation status, and senescence markers (telomere shortening).
Main Results:
- Achieved the highest reported fold expansion of NK cells to date (>47,000-fold in 21 days).
- Generated highly activated and pure NK cells.
- Expanded NK cells showed no signs of senescence, as indicated by preserved telomere length.
Conclusions:
- The K562 mb.IL21 platform provides a highly efficient and robust method for ex vivo NK cell expansion.
- This protocol overcomes key limitations of existing methods, producing functional, non-senescent NK cells.
- The platform holds significant potential for advancing NK cell-based adoptive immunotherapy for cancer treatment.
